Abbot Financial Management Inc. Invests $683,000 in iShares NASDAQ Biotechnology Index (IBB) Stock

Abbot Financial Management Inc. acquired a new position in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 2,204 shares of the financial services provider’s stock, valued at approximately $683,000.

A number of other institutional investors also recently bought and sold shares of the business. Bollard Group LLC lifted its holdings in shares of iShares NASDAQ Biotechnology Index by 0.3% in the 2nd quarter. Bollard Group LLC now owns 392 shares of the financial services provider’s stock valued at $121,000 after buying an additional 1 shares during the period. Sei Investments Co. lifted its holdings in shares of iShares NASDAQ Biotechnology Index by 297.0% in the 1st quarter. Sei Investments Co. now owns 401 shares of the financial services provider’s stock valued at $118,000 after buying an additional 300 shares during the period. Founders Capital Management acquired a new stake in shares of iShares NASDAQ Biotechnology Index in the 1st quarter valued at approximately $150,000. WMS Partners LLC acquired a new stake in shares of iShares NASDAQ Biotechnology Index in the 1st quarter valued at approximately $200,000. Finally, Fairview Capital Investment Management LLC acquired a new stake in shares of iShares NASDAQ Biotechnology Index in the 1st quarter valued at approximately $203,000. 57.77% of the stock is owned by institutional investors.

Shares of iShares NASDAQ Biotechnology Index (NASDAQ IBB) opened at 332.75 on Thursday. The stock has a 50 day moving average price of $319.98 and a 200 day moving average price of $304.88. iShares NASDAQ Biotechnology Index has a 12-month low of $246.71 and a 12-month high of $336.72.

COPYRIGHT VIOLATION WARNING: “Abbot Financial Management Inc. Invests $683,000 in iShares NASDAQ Biotechnology Index (IBB) Stock” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/09/21/abbot-financial-management-inc-invests-683000-in-ishares-nasdaq-biotechnology-index-ibb-stock.html.

Separately, Vetr cut iShares NASDAQ Biotechnology Index from a “buy” rating to a “hold” rating and set a $307.00 price target for the company. in a report on Monday, June 5th.

iShares NASDAQ Biotechnology Index Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares NASDAQ Biotechnology Index (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply